Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Change in Acquisitions & Divestments (2016 - 2025)

Voyager Therapeutics' Change in Acquisitions & Divestments history spans 9 years, with the latest figure at $118.8 million for Q1 2025.

  • For Q1 2025, Change in Acquisitions & Divestments rose 8.06% year-over-year to $118.8 million; the TTM value through Mar 2025 reached $286.3 million, up 46.8%, while the annual FY2025 figure was $262.0 million, 30.02% down from the prior year.
  • Change in Acquisitions & Divestments for Q1 2025 was $118.8 million at Voyager Therapeutics, up from $109.9 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $118.8 million in Q1 2025 and bottomed at $22.6 million in Q2 2021.
  • The 3-year median for Change in Acquisitions & Divestments is $72.5 million (2021), against an average of $71.6 million.
  • The largest YoY upside for Change in Acquisitions & Divestments was 50.88% in 2021 against a maximum downside of 68.33% in 2021.
  • A 3-year view of Change in Acquisitions & Divestments shows it stood at $22.6 million in 2021, then surged by 385.72% to $109.9 million in 2024, then grew by 8.06% to $118.8 million in 2025.
  • Per Business Quant, the three most recent readings for VYGR's Change in Acquisitions & Divestments are $118.8 million (Q1 2025), $109.9 million (Q1 2024), and $22.6 million (Q2 2021).